A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
Raptiva
Synonyms :
efalizumab
Class :
Selective immunosuppressants
Dosage Forms & StrengthsÂ
Powder Â
125 mgÂ
Take an initial dose of 0.7 mg/kg through subcutaneously one time
Take a maintenance dose of 1 mg/kg subcutaneously weekly
Not determined Â
Refer to adult dosingÂ
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may diminish the therapeutic effect of vaccines
poliovirus vaccine inactivated
may diminish the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may have a decreased therapeutic effect when combined with covid-19 vaccine
Immunosuppressants may reduce the therapeutic effect of COVID-19 Vaccine
it may enhance the immunosuppressive effect of Immunosuppressants
it may diminish the therapeutic effect of Influenza Virus Vaccines
influenza virus vaccine h n live
it may diminish the therapeutic effect of Influenza Virus Vaccines
influenza virus vaccine (h n ) adjuvanted
it may diminish the therapeutic effect of Influenza Virus Vaccines
it may diminish the therapeutic effect of Influenza Virus Vaccines
poliovirus vaccine, live, trivalent
immunosuppressants may diminish the therapeutic effect of Vaccines
poliovirus vaccine inactivated
immunosuppressants may diminish the therapeutic effect of Vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
may decrease the therapeutic effect of COVID-19 vaccine
may increase the immunosuppressive effect of tacrolimus
may decrease the therapeutic effect when combined with sipuleucel-t
may decrease the therapeutic effect when combined with vaccines
may decrease the diagnostic effect when combined with coccidioides immitis test
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may increase the immunosuppressive effect of Immunosuppressants
respiratory syncytial virus (RSV) vaccine
may increase the immunosuppressive effect of Immunosuppressants
meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccineÂ
immunosuppressants can decrease the efficacy of the vaccines
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
vaccinia immune globulin intravenous (Rx)
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
poliovirus vaccine, live, trivalent
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
poliovirus vaccine inactivated
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
smallpox (vaccinia) vaccine, live
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
smallpox (vaccinia) vaccine, live
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
Immunosuppressants may enhance the adverse/toxic effect of Vaccines
may enhance the adverse/toxic effect of BCG products
may increase the immunosuppressive effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
vaccinia immune globulin intravenous (Rx)
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
poliovirus vaccine, live, trivalent
may increase the adverse/toxic effect of immunosuppressants
poliovirus vaccine inactivated
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
smallpox (vaccinia) vaccine, live
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
may increase the adverse/toxic effect of immunosuppressants
measles, mumps, rubella and varicella vaccine, liveÂ
may increase the toxic effects of varicella virus containing vaccine
it increases the toxicity of rubella or varicella-containing live vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)Â
may enhance the adverse/toxic effect of rubella, and varicella vaccine, live 
immunosuppressants increase the effect of baricitinib
immunosuppressants increase the toxicity of BCG products
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the effect of immunosuppression of natalizumab
it increases the effect of immunosuppressants
immunosuppressants increase the toxicity of the poliovirus vaccine
immunosuppressants increase the effect of immunosuppression of ruxolitinib
immunosuppressants increase the effect of immunosuppression of tacrolimus
immunosuppressants increase the toxicity of talimogene laherparepvec
immunosuppressants increase the effect of immunosuppression of tofacitinib
immunosuppressants increase the toxicity of the typhoid vaccine
immunosuppressants increase the effect of immunosuppression of upadacitinib
measles, mumps, rubella, and varicella vaccine, live (Rx)
immunosuppressants increase the toxicity of live vaccines
measles mumps and rubella vaccine, live
immunosuppressants increase the toxicity of live vaccines
immunosuppressants increase the toxicity of the yellow fever vaccine
may increase the immunosuppressive effect of immunosuppressive agents
may have an increased immunosuppressive effect when combined with immunosuppressants
may increase the immunosuppressive effect of tacrolimus
may have an increased adverse effect when combined with nadofaragene firadenovec
may have an increasingly adverse effect when combined with immunosuppressants
methotrexate can also enhance the immunosuppressive effect of tacrolimus (Topical)
may have an increased immunosuppressive effect when combined with ritlecitinib
cladribine: they may increase the immunosuppressive effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
respiratory syncytial virus vaccine, adjuvanted
may reduce the therapeutic effect of vaccines
respiratory syncytial virus (RSV) vaccine
may reduce the therapeutic effect of vaccines
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with vaccines
when both drugs are combined, there may be an increased risk or severity of adverse effects 
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections
it may enhance the immunosuppressive effect of immunosuppressants
immunosuppressants may reduce the therapeutic effect of COVID-19 Vaccine
Immunosuppressants may enhance the immunosuppressive effect of Inebilizumab.
may enhance the immunosuppressive effect of baricitinib
immunosuppressants decrease the efficacy of brincidofovir
may increase the therapeutic effect of immunosuppressants
may have an increased immunosuppressive effect when combined with inebilizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ofatumumab
may decrease the therapeutic effect when combined with pidotimod
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with ublituximab
may decrease the therapeutic effect when combined with pneumococcal vaccines
antithymocyte globulin rabbitÂ
may have an increasingly adverse effect when combined with antithymocyte globulin
leniolisib reduces the efficacy of the live rotavirus oral vaccine by exerting immunosuppressive effects
The immunosuppressive effects of obinutuzumab diminish the effectiveness of the live rotavirus oral vaccine
antithymocyte globulin equineÂ
may have an increasingly adverse effect when combined with antithymocyte globulin
respiratory syncytial virus vaccine, adjuvanted
immunosuppressants decrease the efficacy of vaccines
respiratory syncytial virus (RSV) vaccine
immunosuppressants decrease the efficacy of vaccines
may have an increased immunosuppressive effect when combined with immunosuppressants
elevated doses of corticosteroids can inhibit the delayed-type hypersensitivity (DTH) skin test response after a two-week course of treatment
typically, the response reverts to its pre-treatment level within a few weeks after discontinuing steroid therapy
may decrease the therapeutic effect when combined with covid-19 vaccine
the activity of the anthrax vaccine can be reduced when used in combination with efalizumab
immunosuppressants decrease the efficacy of the COVID-19 vaccine
it increases the effect of immunosuppressive agents
immunosuppressants decrease the efficacy of the influenza virus vaccine
immunosuppressants increase the effect of immunosuppression of leflunomide
immunosuppressants decrease the efficacy of the rabies vaccine
measles, mumps, rubella, and varicella vaccine, live (Rx)
immunosuppressants decrease the efficacy of vaccines
measles mumps and rubella vaccine, live
immunosuppressants decrease the efficacy of vaccines
Actions and SpectrumÂ
Efalizumab is a monoclonal antibody that targeted and inhibited the activation and particularly T cells involved in the immune response that contributes to psoriasis.
Frequency not defined Â
Swelling, tenderness, or warmth on the skinÂ
Loss of appetiteÂ
Accumulation of pusÂ
Chest painÂ
Difficulty in breathing or swallowingÂ
Fast heartbeatÂ
Fever or chillsÂ
CoughÂ
DiarrheaÂ
HeadacheÂ
Itching, pain, redness,Â
Muscle or joint stiffness, tightness, or rigidityÂ
NauseaÂ
Black Box WarningÂ
None
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
The mechanism of efalizumab was immunomodulation, specifically the reduction of T-cell activation and migration.Â
PharmacodynamicsÂ
Psoriasis is a skin condition marked by excessive skin cell growth due to an aberrant immune response. Â
Efalizumab helps to relieve the symptoms of this condition.Â
PharmacokineticsÂ
Limited information available on ADME.Â
AdministrationÂ
Efalizumab is administered by subcutaneous injection i.e., injected under the skin.
Patient information leafletÂ
Generic Name: efalizumabÂ
Why do we use efalizumab?Â
Efalizumab was designed to modulate the immune response and reduce the symptoms associated with psoriasis. Â
Efalizumab is used in the treatment of moderate to severe plaque psoriasis.